{"id":170,"date":"2023-02-02T10:00:00","date_gmt":"2023-02-02T10:00:00","guid":{"rendered":"https:\/\/cninmed.com\/en\/?p=170"},"modified":"2025-09-03T03:05:06","modified_gmt":"2025-09-03T03:05:06","slug":"china-bd-2023-zhimeng-biopharma-and-gsk-enters-a-license-on-tlr8a-cb06-036-cb06-for-hbv-treatment","status":"publish","type":"post","link":"https:\/\/cninmed.com\/en\/2023\/170.html","title":{"rendered":"[China BD 2023] Zhimeng Biopharma and GSK enters a license on TLR8A CB06-036 (CB06) for HBV treatment"},"content":{"rendered":"\n<p>Announced Date: 2023-02-01 (February  1, 2023)<\/p>\n\n\n\n<p>Asset Name: CB06-036\uff08CB06\uff09<\/p>\n\n\n\n<p>Licensor: Shanghai Zhimeng Biopharma (China)<\/p>\n\n\n\n<p>Licensee (Buyer): GSK\uff08UK\uff09<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Asset Modality: Small &nbsp;Molecule, oral <\/p>\n\n\n\n<p>Asset Target: TLR8 agonist<\/p>\n\n\n\n<p>Potential Indication: treatment of HBV<\/p>\n\n\n\n<p>Current Stage: Phase I clinical trial\u00a0, China\/US<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Scope of Authority:<\/p>\n\n\n\n<p>In December 2022, Zhimeng Biopharma entered into a Global Exclusive license agreement with GSK for CB06, a TLR8 agonist. Subject to successful completion of phase I, the agreement will allow GSK to develop, manufacture and commercialise CB06 for the treatment of HBV. If successful, CB06 could be used in combination, or as a sequential treatment with bepirovirsen, to potentially deliver a functional cure in more HBV patients.<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Payment Detail:<\/p>\n\n\n\n<p>Undisclosed<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Link:<\/p>\n\n\n\n<p><a href=\"http:\/\/www.core-biopharma.com\/news\/57.html\">Zhimeng Biopharma Entered into A Global Exclusive Licensing Agreement with GlaxoSmithKline in HBV (core-biopharma.com)<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Announced Date: 2023-02-01 (February 1, 2023) Asset Name: CB06-036\uff08CB06\uff09 Licensor: Shanghai Zhimeng Biopharma (China) Licensee (Buyer): &hellip; <a title=\"[China BD 2023] Zhimeng Biopharma and GSK enters a license on TLR8A CB06-036 (CB06) for HBV treatment\" class=\"hm-read-more\" href=\"https:\/\/cninmed.com\/en\/2023\/170.html\"><span class=\"screen-reader-text\">[China BD 2023] Zhimeng Biopharma and GSK enters a license on TLR8A CB06-036 (CB06) for HBV treatment<\/span>Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-170","post","type-post","status-publish","format-standard","hentry","category-china-license-out"],"_links":{"self":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/170","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/comments?post=170"}],"version-history":[{"count":2,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/170\/revisions"}],"predecessor-version":[{"id":172,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/170\/revisions\/172"}],"wp:attachment":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/media?parent=170"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/categories?post=170"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/tags?post=170"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}